Skip to main content
Premium Trial:

Request an Annual Quote

Bjrn Ekstrm, Charles Jeuell, Anna Koostra, Thomas Heydler

Premium

Björn Ekström has become CEO of Olink Bioscience, a Swedish startup focusing on protein analysis technology. Previously, Ekström was head of R&D at Pyrosequencing. He also held several positions within R&D at Amersham Biosciences and Pharmacia Biotech.


Midwest BioResearch, which provides outsourced drug disposition and toxicology services, has appointed Charles Jeuell as its vice president of analytical operations and Anna Koostra as a senior-level research scientist in the company’s protein bioanalysis group, the company said last week.


Thomas Heydler has been appointed the new CEO of Definiens, a Munich, Germany-based company that specializes in providing high-content image analysis software.

Prior to joining Definiens, Heydler was president and CEO at InterPro Business Solutions and Barcelona Design. Before that, he was vice president and executive officer at Documentum, a pharmaceutical and life sciences software company.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.